Vimgreen Pharmaceuticals progresses with Phase 2 trial of VG081821AC for Parkinson’s disease
Vimgreen Pharmaceuticals has marked a significant milestone with the completion of participant enrollment in its Phase 2 clinical trial for VG081821AC, a cutting-edge treatment for ... Read More